# US 2010/0168108 A1 · Phenyl derivatives and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168108 A1
- Document ID: US20100168108A1
- Status: Published application
- Kind: A1
- Application number: 12/689,078
- Filed: 2010-01-18
- Published: 2010-07-01
- Earliest claimed: 2004-10-05
- Assignees: Adolor Corporation
- Inventors: Roland E. Dolle; Karin Worm; Q. Jean Zhou
- Web page: https://patentgrep.com/patent/US20100168108A1

## CPC

- C07D 213/82: in position 3
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 275/24: containing six-membered aromatic rings
- C07C 275/32: being further substituted by singly-bound oxygen atoms
- C07C 311/04: to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 207/28: 2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 285/06: 1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/185: from aliphatic carboxylic acids
- C07D 307/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant.

## Claims

### Claim 1

A compound of formula I:
wherein:
R1, R2, R3, and R4 are each independently H, alkyl, —OR9a, —N(R10)(R11), —C(═O)N(R12)(R13), —C(═O)—OR9b, —OP(═O)(OR9c)(OR9d), —CN, or
R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 8-membered carbocyclic ring, wherein 1 to 3 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—;
each R7 and R8 is independently H, alkyl, halogen, or —OR9f;
A, B, D, and E are each independently N, CR14a, C-[C(R15a)(R16a)]p—N(R17)-G1, or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
J is N or CR14b, provided that no more than two of A, B, D, E, and J are N;
each G1 is independently —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
G2 is alkyl, acyl, aryl, heteroaryl, heterocycloalkyl, —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═O)—OR9b, —C(═CHNO2O)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
each R9a, R9b, R9c, R9d, R9e, and R9f is independently H or alkyl;
each R10, R11, R12, and R13 is independently H, alkyl, alkenyl, aryl, or heteroaryl, or each R10 and R11 or R12 and R13, taken together with the nitrogen atom to which they are attached, independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R14a and R14b is independently H, halogen, alkyl, —CH2F, —CHF2, —CF3, —CN, —(CH2)r—OH, or —(CH2)r—O-alkyl;
each R18a, R18b, R18c, R18d, R18e, R18f, R20a, and R20b is independently H, alkyl, alkenyl, or aryl, or each R18a and R18b or R18c and R18d or R20a and R20b, taken together with the nitrogen atom to which they are attached independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R19 is independently H, alkyl, aryl, OH, or —O-alkyl;
W is a single bond, —O—, —S—, —CH2—, —CF2—, alkylidene, —CH(halogen)-, —CH(OH)—, or —CH(O-alkyl)-, provided that when W is —O— or —S—, then n≧2 and each R7 and R8 is independently H or alkyl;
X is a single bond, —CH═CH—, —O—, or —N(R21)—, provided that when X is —O—, G2 is other than —C(═N—CN)—N(R18e)(R18f); and provided that when X is —O— or —N(R21)—, then R8 is H or alkyl; and provided that when G2 is —C(═CHNO2)—N(R18c)(R18d), then X is —N(R21)—; and
provided that when G2 is heterocycloalkyl or heteroaryl and attached to X through a ring heteroarom, then X is a single bond;
R15a, R15b, R16a, R16b, R17, and R21 is independently H or alkyl; or R17 and R18c, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—; or R18c and R21, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2-alkyl)-;
m and n are each independently an integer from 1 to 5;
each p is independently an integer from 0 to 5; and
each r is independently an integer from 0 to 4;
with the provisos that:
(1) at least one of A, B, D, and E is C—[C(R15a)(R16a)]p—N(R17)-G1 or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b); and
(2) when each R8 is independently H or alkyl, W is a single bond, X is —N(R21), m is 1, and n is 2, then G2 is other than acyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is —OR9a or —N(R10)(R11).

### Claim 3 (depends on 2)

A compound according to claim 2, wherein R1 is —OR9a.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein R1 is —OH.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R3 and R4 are each independently H or alkyl.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein R3 and R4 are each H.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 8-membered carbocyclic ring, wherein one of the ring carbon atoms may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—.

### Claim 8 (depends on 7)

A compound according to claim 7, wherein R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 6-membered carbocyclic ring, wherein one of the ring carbon atoms may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—.

### Claim 9 (depends on 8)

A compound according to claim 8, wherein R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 6-membered carbocyclic ring.

### Claim 10 (depends on 9)

A compound according to claim 9, wherein R5 and R6 are each independently H or alkyl.

### Claim 11 (depends on 10)

A compound according to claim 10 wherein R5 and R6 are methyl.

### Claim 12 (depends on 1)

A compound according to claim 1, wherein R7 and R8 are each independently H or alkyl.

### Claim 13 (depends on 12)

A compound according to claim 12, wherein R7 and R8 are H.

### Claim 14 (depends on 1)

A compound according to claim 1, wherein A, B, D, and E are each independently CR14a, C—[C(R15a)(R16a)]p—N(R17)-G1, or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b).

### Claim 15 (depends on 14)

A compound according to claim 14, wherein A, B, D, and E are each independently CR14a or C—[C(R15a)(R16a)]p—N(R17)-G1.

### Claim 16 (depends on 15)

A compound according to claim 15, wherein G1 is —C(═O)—N(R18c)(R18d) and R17 and R18c, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-.

### Claim 17 (depends on 15)

A compound according to claim 15, wherein R17 is H or alkyl.

### Claim 18 (depends on 15)

A compound according to claim 15, wherein two or three of A, B, D, and E are each independently CR14a.

### Claim 19 (depends on 1)

A compound according to claim 1, wherein J is CR14b.

### Claim 20 (depends on 1)

A compound according to claim 1, wherein each G1 is independently —S(═O)2R19, —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, or —C(═O)—N(R18c)(R18d).

### Claim 21 (depends on 20)

A compound according to claim 20, wherein each G1 is —C(═O)-heteroaryl or —C(═O)—N(R18c)(R18d).

### Claim 22 (depends on 1)

A compound according to claim 1, wherein G2 is —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f).

### Claim 23 (depends on 1)

A compound according to claim 1, wherein G2 is alkyl or —C(═O)—N(R18c)(R18d).

### Claim 24 (depends on 23)

A compound according to claim 23, wherein G2 is —C(═O)—N(R18c)(R18d).

### Claim 25 (depends on 24)

A compound according to claim 24 wherein X is ——N(R21)—, and R18c and R21, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(acyl)-, or —N(S(═O)2-alkyl)-.

### Claim 26 (depends on 24)

A compound according to claim 24, wherein X is a single bond, —CH═CH—, —O—, —N(H)— or —N(alkyl)-

### Claim 27 (depends on 1)

A compound according to claim 1 wherein R9a is H.

### Claim 28 (depends on 1)

A compound according to claim 1, wherein R14a is H.

### Claim 29 (depends on 1)

A compound according to claim 1, wherein R14b is H.

### Claim 30 (depends on 1)

A compound according to claim 1, wherein at least one of R14a and R14b is —(CH2)r—OH or —(CH2)r—O-alkyl.

### Claim 31 (depends on 1)

A compound according to claim 1 wherein each R18c and R18d is independently H, alkyl, or aryl, or each R18c and R18d, taken together with the nitrogen atom to which they are attached independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, or —N(alkyl)-.

### Claim 32 (depends on 31)

A compound according to claim 31 wherein each R18c and R18d is independently H or alkyl optionally substituted with alkoxycarbonyl.

### Claim 33 (depends on 32)

A compound according to claim 32, wherein at least one of R18c and R18d is alkyl substituted with C1-C3 alkoxycarbonyl.

### Claim 34 (depends on 33)

A compound according to claim 33, wherein at least one of R18c and R18d is —CH2C(═O)—OCH2CH3.

### Claim 35 (depends on 31)

A compound according to claim 31, wherein one of R18c and R18d is optionally substituted aryl.

### Claim 36 (depends on 35)

A compound according to claim 35, wherein one of R18c and R18d is phenyl substituted with alkoxy, cyano, or dialkylamino.

### Claim 37 (depends on 36)

A compound according to claim 36, wherein one of R18c and R18d is phenyl substituted with meta-alkoxy, meta-cyano, meta-dialkylamino, para-alkoxy, para-cyano, or para-dialkylamino.

### Claim 38 (depends on 1)

A compound according to claim 1, wherein W is —O— or —CH2—.

### Claim 39 (depends on 1)

A compound according to claim 1, wherein X is a single bond or —N(R21)—.

### Claim 40 (depends on 1)

A compound according to claim 1, wherein at least one of R15a, R16a, and R21 is H.

### Claim 41 (depends on 40)

A compound according to claim 40, wherein R15a, R16a, and R21 are each H.

### Claim 42 (depends on 1)

A compound according to claim 1, wherein at least one of R17 and R18c is H.

### Claim 43 (depends on 1)

A compound according to claim 1, wherein m is 1.

### Claim 44 (depends on 1)

A compound according to claim 1, wherein n is 1 or 2.

### Claim 45 (depends on 1)

A compound according to claim 1, wherein p is 1.

### Claim 46 (depends on 1)

A compound according to claim 1, wherein r is 1 or 2.

### Claim 47 (depends on 1)

A compound according to claim 1, wherein one of A and D is C[—C(R15a)(R16a)]p—N(R17)-G1 or one of B and E is C—[C(R15a)(R16a)]p—N(R17)-G1.

### Claim 48 (depends on 47)

A compound according to claim 47, wherein R17 is H.

### Claim 49 (depends on 48)

A compound according to claim 48, wherein R1 is —OR9a.

### Claim 50 (depends on 49)

A compound according to claim 49 wherein R2, R3, and R4 are each H.

### Claim 51 (depends on 50)

A compound according to claim 50, wherein R5 and R6 are each alkyl.

### Claim 52 (depends on 51)

A compound according to claim 51, wherein R5 and R6 are each independently C1-C3 alkyl.

### Claim 53 (depends on 52)

A compound according to claim 52, wherein R5 and R6 are each methyl.

### Claim 54 (depends on 53)

A compound according to claim 53, wherein R7 and R8 are each H.

### Claim 55 (depends on 54)

A compound according to claim 54, wherein J is CR14b, one of D and E is C—[C(R15a)(R16a)]p—N(R17)-G1, and A and B and the other of D and E are each independently CR14a.

### Claim 56 (depends on 55)

A compound according to claim 55, of formula IIa or IIb:

### Claim 57 (depends on 56)

A compound according to claim 56 of formula IIa or IIb, wherein W is a single bond, —O—, or —CH2—.

### Claim 58 (depends on 57)

A compound according to claim 57, wherein W is —O— or —CH2—.

### Claim 59 (depends on 58)

A compound according to claim 58, wherein n is 1 or 2.

### Claim 60 (depends on 59)

A compound according to claim 59, wherein n is 2.

### Claim 61 (depends on 59)

A compound according to claim 59, wherein X is a single bond, —CH═CH—, or —N(R21)—.

### Claim 62 (depends on 61)

A compound according to claim 61, wherein X is a single bond or —N(R21)—.

### Claim 63 (depends on 61)

A compound according to claim 61, wherein G2 is alkyl, acyl, or —C(═O)—N(R18c)(R18d).

### Claim 64 (depends on 63)

A compound according to claim 63 wherein G2 is C1-C3 alkyl.

### Claim 65 (depends on 63)

A compound according to claim 63 wherein G2 is —C(═O)—C1-C6 alkyl.

### Claim 66 (depends on 63)

A compound according to claim 63, wherein G2 is —C(═O)—N(R18c)(R18d).

### Claim 67 (depends on 63)

A compound according to claim 63, wherein G1 is —C(═O)—N(R18c)(R18d).

### Claim 68 (depends on 67)

A compound according to claim 67, wherein G1 is —C(═O)—NH(C1-C3 alkyl).

### Claim 69 (depends on 63)

A compound according to claim 63, wherein G1 is —C(═O)-heterocycloalkyl.

### Claim 70 (depends on 69)

A compound according to claim 69, wherein G1 is:

### Claim 71 (depends on 63)

A compound according to claim 63, wherein G1 is —S(═O)2-alkyl.

### Claim 72 (depends on 71)

A compound according to claim 71, wherein G1 is —S(═O)2—CH3.

### Claim 73 (depends on 68)

A compound according to claim 68 of formula IIa, wherein G1 is —C(═O)—N(H)CH2CH3, G2 is
X is a single bond, n is 2, p is 1, W is —O—, and R9a, R15a, and R16a are each H.

### Claim 74 (depends on 68)

A compound according to claim 68 of formula IIa, wherein G1 is C(═O)—N(H)CH2CH3, G2 is —C(═O)—C(CH3)3, X is —NH—, n and p are each 1, W is —CH2—, and R9a, R15a, and R16a are each H.

### Claim 75 (depends on 68)

A compound according to claim 68 of formula IIa, wherein G1 is C(═O)—N(H)CH2CH3, G2 is
X is a —NH—, n and p are each 1, W is —CH2—, and R9a, R15a, and R16a are each H.

### Claim 76 (depends on 68)

A compound according to claim 68 of formula IIa, wherein G1 is —C(═O)—N(H)CH3, G2 is
X is a single bond, n is 2, p is 1, W is —CH2—, and R9a, R15a, and R16a are each H.

### Claim 77 (depends on 68)

A compound according to claim 68 of formula IIa, wherein G1 is —C(═O)—N(H)CH2CH3, G2 is
X is a single bond, n is 2, p is 1, W is —CH2—, and R9a, R15a, and R16a are each H.

### Claim 78 (depends on 68)

A compound according to claim 68 of formula IIa, wherein G1 is —C(═O)—N(H)CH(CH3)2, G2 is
X is a single bond, n is 2, p is 1, W is —CH2—, and R9a, R15a, and R16a are each H.

### Claim 79 (depends on 1)

A compound according to claim 1 which exhibits activity toward the cannabinoid receptors.

### Claim 80 (depends on 1)

A compound according to claim 1, wherein each G1 is independently —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f).

### Claim 81 (depends on 1)

A compound according to claim 1, wherein each R17 is independently H or alkyl.

### Claim 82 (depends on 1)

A compound according to claim 1, wherein each G2 is alkyl, acyl, aryl, heteroaryl, heterocycloalkyl, —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═O)—OR9b, or —C(═N—CN)—N(R18e)(R18f).

### Claim 83 (depends on 1)

A compound according to claim 1, wherein R21 is H or alkyl.

### Claim 84 (depends on 1)

A compound according to claim 1 selected from the group consisting of:
1-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-2-yl]-3-ethyl-urea;
N-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-2-yl]-methanesulfonamide;
N-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-3-yl]-methanesulfonamide;
6-(2-hydroxy-3′-methanesulfonylaminobiphenyl-4-yl)-6-methylheptanoic acid methyl ester;
1-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-{2-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-2-yl]-ethyl }-3-ethyl-urea;
N-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-3-ylmethyl]methanesulfonamide;
N-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-2-ylmethyll-methanesulfonamide;
N-{2-[4′-(1,1-dimethylheptyl)-2′-hydroxybiphenyl-2-yl]-ethyl}-methanesulfonamide;
1-{4′-[1,1-dimethyl-2-(3-morpholin-4-yl-3-oxo-propoxy)-ethyl]-2′-hydroxybiphenyl-3-ylmethyl}-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-propyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-propyl-urea;
1-ethyl-3-{2′-hydroxy-4′-[2-(2-methoxyethoxy)-1,1-dimethylethyl]-biphenyl-2ylmethyl}-urea;
1-ethyl-3-{2′-hydroxy-4′-[2-(2-methoxyethoxy)-1,1-dimethylethyl]-biphenyl-3ylmethyl}-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hex-4-enyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-isopropyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-(4-methoxyphenyl)-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-ureido}-acetic acid ethyl ester;
1-(4-dimethylaminophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-urea;
1-(3-cyanophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-(3-methoxyphenyl)-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-isopropyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-(4-methoxyphenyl)-urea;
{3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-ureido}-acetic acid ethyl ester;
1-(4-dimethylaminophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-urea;
1-(3-cyanophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-(3-methoxyphenyl)-urea;
1-(4-{2′-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-3-isopropylurea;
1-(4-{3′-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-3-isopropylurea;
ethylcarbamic acid 4-{3′-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl ester;
ethylcarbamic acid 4-{2′-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl ester;
morpholine-4-carboxylic acid (4-{3′-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-amide;
tetrahydrofuran-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
furan-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
furan-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
isoxazole-5-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
2,5-dimethylfuran-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
N-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-nicotinamide;
pyrazine-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
1-methyl-1H-pyrrole-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
5-methylisoxazole-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
thiophene-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
5-oxo-pyrrolidine-2-carboxylic acid[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
[1,2,3]-thiadiazole-4-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
5-methylpyrazine-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
N-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-1-hydroxyisonicotinamide N-oxide;
1,5-dimethyl-1H-pyrazole-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
tetrahydrofuran-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide
furan-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
furan-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
isoxazole-5-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
2,5-dimethylfuran-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
N-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-nicotinamide;
pyrazine-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
1-methyl-1H-pyrrole-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
5-methylisoxazole-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
thiophene-3-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
5-oxopyrrolidine-2-carboxylic acid[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
[1,2,3]-thiadiazole-4-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
5-methylpyrazine-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-amide;
tetrahydrofuran-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
furan-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-methanesulfonamide;
4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-methanesulfonamide;
N-(4-(3′-((3-ethylureido)-methyl)-2-hydroxybiphenyl-4-yl)-4-methylpentyl)-nicotinamide;
1-ethyl-3-((2′-methoxy-4′-(2-methyl-7-morpholino-7-oxoheptan-2-yl)-biphenyl-3-yl)methyl)urea;
1-ethyl-3-((2′-hydroxy-4′-(2-methyl-7-morpholinoheptan-2-yl)-biphenyl-3-yl)methyl)-urea; and
1-ethyl-3-((2′-hydroxy-4′-(2-methyl-5-(neopentylamino)-pentan-2-yl)biphenyl-3-yl)-methyl)urea;
or a pharmaceutically acceptable salt thereof.

### Claim 85 (depends on 84)

A compound according to claim 84 selected from the group consisting of:
1-{4′-[1,1-dimethyl-2-(3-morpholin-4-yl-3-oxo-propoxy)-ethyl]-2′-hydroxybiphenyl-3-ylmethyl}-3-ethyl-urea;
morpholine-4-carboxylic acid (4-{3′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-amide;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-isopropyl-urea;
1-(4-{3′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-3-isopropyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hex-4-enyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-isopropyl-urea;
tetrahydrofuran-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
N-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-methanesulfonamide;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-propyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-propyl-urea;
1-ethyl-3-{2′-hydroxy-4′-[2-(2-methoxyethoxy)-1,1-dimethylethyl]-biphenyl-2-ylmethyl}-urea;
1-ethyl-3-{2′-hydroxy-4′-[2-(2-methoxyethoxy)-1,1-dimethylethyl]-biphenyl-3-ylmethyl}-urea;
1-[4′-(1,1-dimethyl-heptyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-(4-{2′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-3-isopropyl-urea;
ethylcarbamic acid 4-13′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl ester;
ethylcarbamic acid 4-12′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl ester;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-(4-methoxyphenyl)-urea;
{3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-ureido}-acetic acid ethyl ester;
1-(4-dimethylaminophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-urea;
1-(3-cyanophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-(3-methoxyphenyl)-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-(4-methoxyphenyl)-urea;
{3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-ureido}-acetic acid ethyl ester;
1-(4-dimethylaminophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-urea;
1-(3-cyanophenyl)-3-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-urea; and
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-(3-methoxyphenyl)-urea;
or a pharmaceutically acceptable salt thereof.

### Claim 86 (depends on 85)

A compound according to claim 85 selected from the group consisting of:
1-{4′-[1,1-dimethyl-2-(3-morpholin-4-yl-3-oxo-propoxy)-ethyl]-2′-hydroxybiphenyl-3-ylmethyl}-3-ethyl-urea;
morpholine-4-carboxylic acid (4-13′-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-amide;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-isopropyl-urea;
1-(4-{3′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-3-isopropyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2’-hydroxybiphenyl-2-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(41,1-dimethyl-6-morpholin-4-yl-6-oxo-hex-4-enyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-isopropyl-urea;
tetrahydrofuran-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide;
N-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-methanesulfonamide;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-propyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(2-butoxy-1,1-dimethylethyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-propyl-urea;
1-ethyl-3-{2′-hydroxy-4′-[2-(2-methoxyethoxy)-1,1-dimethylethyl]-biphenyl-2-ylmethyl}-urea; and
1-ethyl-3-{2′-hydroxy-4′-[2-(2-methoxyethoxy)-1,1-dimethylethyl]-biphenyl-3-ylmethyl}-urea;
or a pharmaceutically acceptable salt thereof.

### Claim 87 (depends on 86)

A compound according to claim 86 selected from the group consisting of:
1-{4′-[1,1-dimethyl-2-(3-morpholin-4-yl-3-oxo-propoxy)-ethyl]-2′-hydroxybiphenyl-3-ylmethyl}-3-ethyl-urea;
morpholine-4-carboxylic acid (4-{3′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-amide;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-isopropyl-urea;
1-(4-{3′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-3-isopropyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hex-4-enyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-ethyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-2-ylmethyl]-3-isopropyl-urea;
tetrahydrofuran-2-carboxylic acid [4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-amide; and
N-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-methanesulfonamide;
or a pharmaceutically acceptable salt thereof.

### Claim 88 (depends on 87)

A compound according to claim 87 selected from the group consisting of:
1-{4′-[1,1-dimethyl-2-(3-morpholin-4-yl-3-oxo-propoxy)-ethyl]-2′-hydroxybiphenyl-3-ylmethyl}-3-ethyl-urea;
morpholine-4-carboxylic acid (4-{3′-[(3-ethyl-ureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-amide;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-methyl-urea;
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-ethyl-urea; and
1-[4′-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)-2′-hydroxybiphenyl-3-ylmethyl]-3-urea;
or a pharmaceutically acceptable salt thereof.

### Claim 89 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1.

### Claim 90 (depends on 89)

A pharmaceutical composition according to claim 89, further comprising at least one cannabinoid.

### Claim 91 (depends on 90)

A pharmaceutical composition according to claim 90, wherein the cannabinoid is Δ9-tetrahydrocannabinol or cannabidiol.

### Claim 92 (depends on 89)

A pharmaceutical composition according to claim 89, further comprising at least one opioid.

### Claim 93 (depends on 92)

A pharmaceutical composition according to claim 92, wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol, and mixtures thereof.

### Claim 94 (depends on 89)

A pharmaceutical composition according to claim 89, further comprising at least one analgesic.

### Claim 95 (depends on 94)

A pharmaceutical composition according to claim 94,
wherein the analgesic is a COX2 inhibitor, aspirin, acetaminophen, ibuprophen, or naproxen, or a mixture thereof.

### Claim 96 (depends on 89)

A pharmaceutical composition according to claim 89, further comprising at least one agent selected from the group consisting of an anti seizure agent, an anti-depressant, an NMDA receptor antagonist, an ion channel antagonist, a nicotinic receptor agonist, an anti-Parkinson's agent, and mixtures thereof.

### Claim 97 (depends on 96)

A pharmaceutical composition according to claim 96 wherein said anti-seizure agent is carbamazepine, gabapentin, lamotrigine, or phenytoin, or a mixture thereof.

### Claim 98 (depends on 96)

A pharmaceutical composition according to claim 96 wherein said anti-depressant is amitryptiline.

### Claim 99 (depends on 96)

A pharmaceutical composition according to claim 96, wherein said antiParkinson's agent is deprenyl, amantadine, levodopa, or carbidopa, or a mixture thereof.

### Claim 100

A method of binding cannabinoid receptors in a patient in need thereof, comprising the step of:
administering to said patient an effective amount of a compound of formula I:
wherein:
R1, R2, R3, and R4 are each independently H, alkyl, —OR9a, —N(R10)(R11), —C(═O)N(R12)(R13), —C(═O)—OR9b, —OP(═O)(OR9c)(OR9d), —CN, or
R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 8-membered carbocyclic ring, wherein 1 to 3 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—;
each R7 and R8 is independently H, alkyl, halogen, or —OR9f;
A, B, D, and E are each independently N, CR14a, C—[C(R15a)(R16a)]p—N(R17)-G1, or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
J is N or CR14b, provided that no more than two of A, B, D, E, and J are N;
each G1 is independently —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)-N(R18c)(R18d), —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
G2 is alkyl, acyl, aryl, heteroaryl, heterocycloalkyl, —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═O)—OR9b, —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
each R9a, R9b, R9c, R9d, R9e, and R9f is independently H or alkyl;
each R10, R11, R12, and R13 is independently H, alkyl, alkenyl, aryl, or heteroaryl, or each R10 and R11 or R12 and R13, taken together with the nitrogen atom to which they are attached, independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R14a and R14b is independently H, halogen, alkyl, —CH2F, —CHF2, —CF3, —CN, —(CH2)r—OH, or —(CH2)r—O-alkyl;
each R18a, R18b, R18c, R18d, R18e, R18f, R20a, and R20b is independently H, alkyl, alkenyl, or aryl, or each R18a and R18b or R18c and R18d or R20a and R20b, taken together with the nitrogen atom to which they are attached independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R19 is independently H, alkyl, aryl, OH, or —O-alkyl;
W is a single bond, —O—, —S—, —CH2—, —CF2—, alkylidene, —CH(halogen)-, —CH(OH)—, or —CH(O-alkyl)-, provided that when W is —O— or —S—, then n≧2 and each R7 and R8 is independently H or alkyl;
X is a single bond, —CH═CH—, —O—, or —N(R21)—, provided that when X is —O—, G2 is other than —C(═N—CN)—N(R18e)(R18f); and provided that when X is —O— or —N(R21)—, then R8 is H or alkyl; and provided that when G2 is —C(═CHNO2)—N(R18c)(R18d), then X is —N(R21)—; and
provided that when G2 is heterocycloalkyl or heteroaryl and attached to X through a ring heteroarom, then X is a single bond;
R15a, R15b, R16a, R16b, R17, and R21 is independently H or alkyl; or R17 and R18c, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—; or R18c and R21, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2-alkyl)-;
m and n are each independently an integer from 1 to 5;
each p is independently an integer from 0 to 5; and
each r is independently an integer from 0 to 4;
with the proviso that:
at least one of A, B, D, and E is C—[C(R15a)(R16a)]p—N(R17)-G1 or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
or a pharmaceutically acceptable salt thereof.

### Claim 101 (depends on 100)

A method according to claim 100, wherein said cannabinoid receptors are selected from the group consisting of CB1 and CB2 cannabinoid receptors.

### Claim 102 (depends on 100)

A method according to claim 100, wherein said cannabinoid receptors are located in the central nervous system.

### Claim 103 (depends on 100)

A method according to claim 100, wherein said cannabinoid receptors are located peripherally to the central nervous system.

### Claim 104 (depends on 101)

A method according to claim 101, wherein said compound selectively binds the CB2 cannabinoid receptors relative to the CB1 cannabinoid receptors.

### Claim 105 (depends on 101)

A method according to claim 101, wherein said compound selectively binds the CB1 cannabinoid receptors relative to the CB2 cannabinoid receptors.

### Claim 106 (depends on 100)

A method according to claim 100, wherein the binding agonizes the activity of the cannabinoid receptors.

### Claim 107 (depends on 100)

A method according to claim 100, wherein said compound does not substantially cross the blood-brain barrier.

### Claim 108 (depends on 100)

A method according to claim 100, further comprising administering to said patient an effective amount of at least one cannabinoid.

### Claim 109 (depends on 108)

A method according to claim 108, wherein said cannabinoid is Δ9-tetrahydrocannabinol or cannabidiol.

### Claim 110 (depends on 100)

A method according to claim 100, further comprising administering to said patient an effective amount of at least one opioid.

### Claim 111 (depends on 110)

A method according to claim 110, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol, and mixtures thereof.

### Claim 112 (depends on 100)

A method according to claim 100 wherein said patient is in need of treatment or prevention of a disease or disorder selected from the group consisting of pain, a gastrointestinal disorder, a genitourinary disorder, inflammation, glaucoma, an auto-immune disease, an ischemic condition, an immune-related disorder, a neurodegenerative disease, and combinations thereof.

### Claim 113 (depends on 112)

A method according to claim 112, wherein the disease or disorder is pain.

### Claim 114 (depends on 112)

A method according to claim 112, wherein said pain is inflammatory pain, neuropathic pain, visceral pain, surgical pain, post-surgical pain, cancer related pain or a combination thereof.

### Claim 115 (depends on 113)

A method according to claim 113, wherein said compound of formula I is administered intravenously.

### Claim 116 (depends on 112)

A method according to claim 112, wherein said gastrointestinal disorder is nausea, vomiting, loss of appetite, cachexia, diarrhea, inflammatory bowel disease, irritable bowel syndrome or a combination thereof.

### Claim 117 (depends on 112)

A method according to claim 112, wherein said genitourinary disorder is bladder dysfunction, nephritis or a combination thereof.

### Claim 118 (depends on 112)

A method according to claim 112, wherein said auto-immune disease is multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, osteoporosis, or a combination thereof.

### Claim 119 (depends on 112)

A method according to claim 112, wherein said ischemic condition is renal ischemia, cerebral stroke, cerebral ischemia, or a combination thereof.

### Claim 120 (depends on 112)

A method according to claim 112, wherein said immune-related disorder is asthma, chronic pulmonary obstructive disorder, emphysema, bronchitis, allergy, tissue rejection in organ transplants, celiac disease, Sjogren's syndrome, or a combination thereof.

### Claim 121 (depends on 112)

A method according to claim 112, wherein said neurodegenerative disease is Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, or a combination thereof.

### Claim 122 (depends on 121)

A method according to claim 121, further comprising administering to said patient deprenyl, amantadine, levodopa, or carbidopa.

### Claim 123 (depends on 115)

A method according to claim 115, further comprising administering to said patient codeine, carbamazepine, gabapentin, lamotrigine, phenytoin, amitryptiline, an NMDA receptor antagonist, an ion channel antagonist, a nicotinic receptor agonist, or a mixture thereof.

### Claim 124

A method of providing cardioprotection against ischemic and reperfusion effects in a patient in need thereof, comprising the step of:
administering to said patient an effective amount of a compound of formula I:
wherein:
R1, R2, R3, and R4 are each independently H, alkyl, —OR9a, —N(R10)(R11), —C(═O)N(R12)(R13), —C(═O)—OR9b, —OP(═O)(OR9c)(OR9d), —CN, or
R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 8-membered carbocyclic ring, wherein 1 to 3 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—;
each R7 and R8 is independently H, alkyl, halogen, or —OR9f;
A, B, D, and E are each independently N, CR14a, C—[C(R15a)(R16a)]p—N(R17)-G1, or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
J is N or CR14b, provided that no more than two of A, B, D, E, and J are N;
each G1 is independently —S(═O)2R19, —S(═O)2N(R20a)(R201), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
G2 is alkyl, acyl, aryl, heteroaryl, heterocycloalkyl, —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═O)—OR9b, —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
each R9a, R9b, R9c, R9d, R9e, and R9f is independently H or alkyl;
each R10, R11, R12, and R13 is independently H, alkyl, alkenyl, aryl, or heteroaryl, or each R10 and R11 or R12 and R13, taken together with the nitrogen atom to which they are attached, independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R14a and R14b is independently H, halogen, alkyl, —CH2F, —CHF2, —CF3, —CN, —(CH2), —OH, or —(CH2), —O-alkyl;
each R18a, R18b, R18c, R18d, R18e, R18f, R20a, and R20b is independently H, alkyl, alkenyl, or aryl, or each R18a and R18b or R18c and R18d or R20a and R20b, taken together with the nitrogen atom to which they are attached independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R19 is independently H, alkyl, aryl, OH, or —O-alkyl;
W is a single bond, —O—, —S—, —CH2—, —CF2—, alkylidene, —CH(halogen)-, —CH(OH)—, or —CH(O-alkyl)-, provided that when W is —O— or —S—, then n≧2 and each R7 and R8 is independently H or alkyl;
X is a single bond, —CH═CH—, —O—, or —N(R21)—, provided that when X is —O—, G2 is other than —C(═N—CN)—N(R18e)(R18f); and provided that when X is —O— or —N(R21)—, then R8 is H or alkyl; and provided that when G2 is —C(═CHNO2)—N(R18c)(R18d), then X is —N(R21)—; and provided that when G2 is heterocycloalkyl or heteroaryl and attached to X through a ring heteroarom, then X is a single bond;
each R15a, R15b, R16a, R16b, R17, and R21 is independently H or alkyl; or R17 and R18c, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—; or R18c and R21, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2-alkyl)-;
m and n are each independently an integer from 1 to 5;
each p is independently an integer from 0 to 5; and
each r is independently an integer from 0 to 4;
with the proviso that:
at least one of A, B, D, and E is C—[C(R15a)(R16a)]p—N(R17)-G1 or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
or a pharmaceutically acceptable salt thereof.

### Claim 125 (depends on 124)

A method according to claim 124, wherein the ischemic or reperfusion effect is arrhythmia or hypertension.

### Claim 126

A method of inducing apoptosis in malignant cells, comprising the step of:
contacting said cells with an effective amount of a compound of formula I:
wherein:
R1, R2, R3, and R4 are each independently H, alkyl, —OR9a, —N(R10)(R11), —C(═O)N(R12)(R13), —C(═O)—OR9b, —OP(═O)(OR9c)(OR9d), —CN, or
R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 8-membered carbocyclic ring, wherein 1 to 3 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—;
each R7 and R8 is independently H, alkyl, halogen, or —OR9f;
A, B, D, and E are each independently N, CR14a, C—[C(R15a)(R16a)]p—N(R17)-G1, or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
J is N or CR14b, provided that no more than two of A, B, D, E, and J are N;
each G1 is independently —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
G2 is alkyl, acyl, aryl, heteroaryl, heterocycloalkyl, —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═O)—OR9b, —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
each R9a, R9b, R9c, R9d, R9e, and R9f is independently H or alkyl;
each R10, R11, R12, and R13 is independently H, alkyl, alkenyl, aryl, or heteroaryl, or each R10 and R11 or R12 and R13, taken together with the nitrogen atom to which they are attached, independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R14a and R14b is independently H, halogen, alkyl, —CH2F, —CHF2, —CF3, —CN, —(CH2)r—OH, or —(CH2)r—O-alkyl;
each R18a, R18b, R18c, R18d, R18e, R18f, R20a, and R20b is independently H, alkyl, alkenyl, or aryl, or each R18a and R18b or R18c and R18d or R20a and R20b, taken together with the nitrogen atom to which they are attached independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R19 is independently H, alkyl, aryl, OH, or —O-alkyl;
W is a single bond, —O—, —S—, —CH2—, —CF2—, alkylidene, —CH(halogen)-, —CH(OH)—, or —CH(O-alkyl)-, provided that when W is —O— or —S—, then n≧2 and each R7 and R8 is independently H or alkyl;
X is a single bond, —CH═CH—, —O—, or —N(R21)—, provided that when X is —O—, G2 is other than —C(═N—CN)—N(R18e)(R18f); and provided that when X is —O— or —N(R21)—, then R8 is H or alkyl; and provided that when G2 is —C(═CHNO2)—N(R18c)(R18d), then X is —N(R21)—; and provided that when G2 is heterocycloalkyl or heteroaryl and attached to X through a ring heteroarom, then X is a single bond;
each R15a, R15b, R16a, R16b, R17, and R21 is independently H or alkyl; or R17 and R18c, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—; or R18c and R21, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2-alkyl)-;
m and n are each independently an integer from 1 to 5;
each p is independently an integer from 0 to 5; and
each r is independently an integer from 0 to 4;
with the proviso that:
at least one of A, B, D, and E is C—[C(R15a)(R16a)]p—N(R17)-G1 or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
or a pharmaceutically acceptable salt thereof.

### Claim 127 (depends on 126)

A method according to claim 126, wherein said apoptosis occurs in vitro.

### Claim 128 (depends on 127)

A method according to claim 127, wherein said apoptosis occurs in vivo.

### Claim 129

A method for modulating appetite, comprising the step of:
administering to said patient an effective amount of a compound of formula I:
wherein:
R1, R2, R3, and R4 are each independently H, alkyl, —OR9a, —N(R10)(R11), —C(═O)N(R12)(R13), —C(═O)—OR9b, —OP(═O)(OR9c)(OR9d), —CN, or
R5 and R6 are each independently H or alkyl, or taken together with the carbon atom to which they are attached form a 3- to 8-membered carbocyclic ring, wherein 1 to 3 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, or —N(R9e)—;
each R7 and R8 is independently H, alkyl, halogen, or —OR9f;
A, B, D, and E are each independently N, CR14a, C—[C(R15a)(R16a)]p—N(R17)-G1, or C—[C(R15b)(R16b)]pOC(═O)—N(R18a)(R18b);
J is N or CR14b, provided that no more than two of A, B, D, E, and J are N;
each G1 is independently —S(═O)2R19, —S(═O)2N(R20a)(R20b)C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
G2 is alkyl, acyl, aryl, heteroaryl, heterocycloalkyl, —S(═O)2R19, —S(═O)2N(R20a)(R20b), —C(═O)-heterocycloalkyl, —C(═O)-heteroaryl, —C(═O)—N(R18c)(R18d), —C(═O)—OR9b, —C(═CHNO2)—N(R18c)(R18d), or —C(═N—CN)—N(R18e)(R18f);
each R9a, R9b, R9c, R9d, R9e, and R9f is independently H or alkyl;
each R10, R11, R12, and R13 is independently H, alkyl, alkenyl, aryl, or heteroaryl, or each R10 and R11 or R12 and R13, taken together with the nitrogen atom to which they are attached, independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R14a and R14b is independently H, halogen, alkyl, —CH2F, —CHF2, —CF3, —CN, —(CH2)r—OH, or —(CH2)r—O-alkyl;
each R18a, R18b, R18c, R18d, R18e, R18f, R20a, and R20b is independently H, alkyl, alkenyl, or aryl, or each R18a and R18b or R18c and R18d or R20a and R20b, taken together with the nitrogen atom to which they are attached independently form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—;
each R19 is independently H, alkyl, aryl, OH, or —O-alkyl;
W is a single bond, —O—, —S—, —CH2—, —CF2—, alkylidene, —CH(halogen)-, —CH(OH)—, or —CH(O-alkyl)-, provided that when W is —O— or —S—, then n≧2 and each R7 and R8 is independently H or alkyl;
X is a single bond, —CH═CH—, —O—, or —N(R21)—, provided that when X is —O—, G2 is other than —C(═N—CN)—N(R18e)(R18f); and provided that when X is —O— or —N(R21)—, then R8 is H or alkyl; and provided that when G2 is —C(═CHNO2)—N(R18c)(R18d), then X is —N(R21)—; and
provided that when G2 is heterocycloalkyl or heteroaryl and attached to X through a ring heteroarom, then X is a single bond;
each R15a, R15b, R16a, R16b, R17, and R21 is independently H or alkyl; or R17 and R18c, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2—R9a)—; or R18c and R21, taken together with the atoms through which they are connected form a 4- to 8-membered heterocyclic ring wherein 1 or 2 of the ring carbon atoms independently may be optionally replaced by —O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —N(alkyl)-, —N(C(═O)—R9a)—, or —N(S(═O)2-alkyl)-;
m and n are each independently an integer from 1 to 5;
each p is independently an integer from 0 to 5; and
each r is independently an integer from 0 to 4;
with the proviso that:
at least one of A, B, D, and E is C—[C(R15a)(R16a)]p—N(R17)-G1 or C—[C(R15b)(R16b)]p—OC(═O)—N(R18a)(R18b);
or a pharmaceutically acceptable salt thereof.
